Literature DB >> 6762086

Clinical problems in radiotherapy of carcinoma of the pancreas.

J R Castro, W M Saunders, J M Quivey, G T Chen, J M Collier, K H Woodruff, J T Lyman, P Twomey, C Frey, T L Phillips.   

Abstract

Since 1975, 94 patients with localized unresectable carcinoma of the pancreas have been irradiated using helium and heavier particles at the University of California Lawrence Berkeley Laboratory. Despite surgical exploration and an extensive diagnostic workup including radiological, nuclear medicine, and computer-assisted tomographic studies, many patients proved to have occult liver metastases manifested within 9 months post treatment. In addition, local and regional control of the primary neoplasm (approximately 20%) has been difficult to obtain even with doses of 6000 equivalent rad in 7 1/2 weeks. Gastric and biliary obstruction have required surgical bypass procedures since irradiation has not been successful in relieving obstructive symptoms. Evidence of gastrointestinal injury has been present in postradiation therapy in approximately 10% of patients, a figure which might be higher if more patients had a longer survival (average 10 months). Some patients require pancreatic enzyme supplementation because of pancreatic deficiency either secondary to tumor or treatment. Further improvement in local control and survival requires better diagnostic methods for evaluation of local and metastatic spread, improved therapy for local and regional disease, as well as therapy directed at occult liver metastases that are frequently present.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6762086     DOI: 10.1097/00000421-198212000-00004

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  6 in total

Review 1.  Current and emerging treatments for pancreatic cancer.

Authors:  W F Regine; W J John; M Mohiuddin
Journal:  Drugs Aging       Date:  1997-10       Impact factor: 3.923

2.  Intraoperative electron beam therapy for unresectable cancer of the pancreas.

Authors:  R R Dobelbower; A elTaki; F Bagne; M I Ajlouni; A J Milligan; D G Bronn
Journal:  Int J Pancreatol       Date:  1989-02

3.  Intraoperative radiation enhances decline of pancreatic exocrine function after pancreatic head resection.

Authors:  K Yamaguchi; K Nakamura; M Kimura; K Yokohata; H Noshiro; K Chijiiwa; M Tanaka
Journal:  Dig Dis Sci       Date:  2000-06       Impact factor: 3.199

Review 4.  LB100, a small molecule inhibitor of PP2A with potent chemo- and radio-sensitizing potential.

Authors:  Christopher S Hong; Winson Ho; Chao Zhang; Chunzhang Yang; J Bradley Elder; Zhengping Zhuang
Journal:  Cancer Biol Ther       Date:  2015-04-21       Impact factor: 4.742

5.  Treatment of pancreatic cancer by radiation therapy.

Authors:  R R Dobelbower; A J Milligan
Journal:  World J Surg       Date:  1984-12       Impact factor: 3.352

6.  Towards clinical evidence in particle therapy: ENLIGHT, PARTNER, ULICE and beyond.

Authors:  Stephanie E Combs; Manjit Djosanjh; Richad Pötter; Roberto Orrechia; Thomas Haberer; Marco Durante; Piero Fossati; Katia Parodi; Jacques Balosso; Ugo Amaldi; Michael Baumann; Jürgen Debus
Journal:  J Radiat Res       Date:  2013-07       Impact factor: 2.724

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.